Recombinant Human Thrombopoietin

Generic Name
Recombinant Human Thrombopoietin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
E2E529W34D
Background

Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. This drug is used in the treatment of thrombocytopenia.

Indication

用于治疗实体肿瘤化疗后所致的血小板减少症，使用对象为血小板低于50×109/L且医生认为有必要升高血小板数目。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

First Posted Date
2020-08-18
Last Posted Date
2020-09-01
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
120
Registration Number
NCT04516837
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: rhTPO
First Posted Date
2019-11-19
Last Posted Date
2019-11-19
Lead Sponsor
Huihan Wang
Target Recruit Count
20
Registration Number
NCT04168138
Locations
🇨🇳

ShengJing Hospital of China Medical University, Shenyang, Liaoning, China

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

First Posted Date
2019-01-30
Last Posted Date
2019-01-30
Lead Sponsor
Fudan University
Target Recruit Count
50
Registration Number
NCT03823079

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

First Posted Date
2018-12-11
Last Posted Date
2019-11-15
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
96
Registration Number
NCT03771378
Locations
🇨🇳

Zhou Yiming, Wuhan, Hubei, China

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

First Posted Date
2018-09-17
Last Posted Date
2020-03-23
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
58
Registration Number
NCT03673215
Locations
🇨🇳

302 Military Hospital of China, Beijing, Beijing, China

High-dose Use of rhTPO in CIT Patients

Phase 4
Conditions
Thrombocytopenia
Interventions
Drug: rhTPO
First Posted Date
2018-08-16
Last Posted Date
2018-10-30
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
50
Registration Number
NCT03633019
Locations
🇨🇳

First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

First Posted Date
2018-05-03
Last Posted Date
2022-07-27
Lead Sponsor
Shenzhen Second People's Hospital
Target Recruit Count
98
Registration Number
NCT03515096
Locations
🇨🇳

Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

First Posted Date
2018-04-10
Last Posted Date
2018-04-10
Lead Sponsor
Shandong University
Target Recruit Count
90
Registration Number
NCT03492515
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

First Posted Date
2017-01-09
Last Posted Date
2019-12-06
Lead Sponsor
Hongnan Mo
Target Recruit Count
50
Registration Number
NCT03014102
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia

Phase 2
Conditions
Anemia, Aplastic
Interventions
Drug: placebo
Drug: rhTPO
First Posted Date
2016-08-05
Last Posted Date
2016-08-05
Lead Sponsor
Tianjin Medical University General Hospital
Target Recruit Count
250
Registration Number
NCT02857530
Locations
🇨🇳

Zonghong Shao, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy